BidaskClub downgraded shares of EXACT Sciences (NASDAQ:EXAS) from a buy rating to a hold rating in a research report released on Wednesday, BidAskClub reports.

EXAS has been the subject of a number of other reports. Craig Hallum lifted their price target on shares of 1-800-Flowers.Com from $26.00 to $20.00 and gave the stock a buy rating in a research note on Wednesday, May 1st. Zacks Investment Research upgraded shares of Flagstar Bancorp from a hold rating to a buy rating and set a $38.00 price target for the company in a research note on Monday, July 8th. UBS Group lowered shares of Advanced Disposal Services from a buy rating to a neutral rating and set a $33.00 price target for the company. in a research note on Wednesday, May 1st. They noted that the move was a valuation call. Canaccord Genuity lifted their price target on shares of TELUS from C$51.00 to C$52.00 in a research note on Wednesday, May 1st. Finally, BTIG Research lifted their price target on shares of Apple to $234.00 and gave the stock a buy rating in a research note on Wednesday, May 1st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eleven have given a buy rating to the stock. The stock has a consensus rating of Buy and an average target price of $109.82.

NASDAQ:EXAS opened at $114.88 on Wednesday. The company has a market cap of $14.84 billion, a price-to-earnings ratio of -84.47 and a beta of 1.64. The company has a debt-to-equity ratio of 1.02, a quick ratio of 8.13 and a current ratio of 8.39. EXACT Sciences has a fifty-two week low of $47.78 and a fifty-two week high of $121.98. The company’s 50-day moving average price is $113.12.

EXACT Sciences (NASDAQ:EXAS) last released its quarterly earnings data on Tuesday, April 30th. The medical research company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.01). The firm had revenue of $162.00 million for the quarter, compared to the consensus estimate of $153.07 million. EXACT Sciences had a negative net margin of 41.58% and a negative return on equity of 28.83%. The firm’s revenue for the quarter was up 79.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.33) earnings per share. Sell-side analysts anticipate that EXACT Sciences will post -2.2 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently bought and sold shares of EXAS. Norges Bank purchased a new position in shares of EXACT Sciences in the fourth quarter worth approximately $67,273,000. Pictet Asset Management Ltd. purchased a new position in shares of EXACT Sciences in the first quarter worth approximately $14,232,000. Kornitzer Capital Management Inc. KS boosted its holdings in shares of EXACT Sciences by 286.0% in the first quarter. Kornitzer Capital Management Inc. KS now owns 218,165 shares of the medical research company’s stock worth $18,897,000 after buying an additional 161,640 shares during the last quarter. CIBC Private Wealth Group LLC boosted its holdings in shares of EXACT Sciences by 15.5% in the first quarter. CIBC Private Wealth Group LLC now owns 1,049,462 shares of the medical research company’s stock worth $90,904,000 after buying an additional 140,825 shares during the last quarter. Finally, Spark Investment Management LLC purchased a new position in shares of EXACT Sciences in the first quarter worth approximately $11,364,000. 86.65% of the stock is currently owned by institutional investors.

About EXACT Sciences

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.

Further Reading: How does new data get added to a blockchain?

Analyst Recommendations for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.